The syriQ BioPure from Schott Pharma - glass syringes tuned for sensitive biologics
29.06.2026 - 03:27:46 | ad-hoc-news.de
Reviewed: ad hoc news Bestseller & Flagship desk. Edited and checked on 2026-06-29, 03:27. Details in the imprint.
The syriQ BioPure prefillable syringe from Schott Pharma sits cold and clear in the hand, a slim glass barrel with a smooth silicone glide that barely whispers when you press the plunger. It is built for fragile biologics that do not forgive rough handling.
What syriQ BioPure is built for
SyriQ BioPure is a line of prefillable glass syringes designed specifically for protein-based biologic drugs, such as monoclonal antibodies and high-concentration formulations. These drugs are sensitive to particles and surface interactions that can trigger aggregation.
Schott Pharma tailors the inner surface treatment and lubrication of syriQ BioPure to minimize interaction between the drug and the glass or silicone, aiming to cut down visible and subvisible particles during storage and injection. This helps manufacturers meet strict regulatory expectations for injectable biologics.
How the syringe system is configured
SyriQ BioPure syringes are typically delivered as ready-to-fill components in standard volumes like 1.0 ml and 2.25 ml, with precisely formed glass barrels and tight dimensional tolerances so they run cleanly on high-speed filling lines. The aim is to reduce rejects and keep yield high in commercial production.
Schott Pharma offers different needle and closure configurations within the syriQ BioPure range, allowing pharma customers to match the system to subcutaneous or intravenous administration while keeping the same core glass and coating concept. That flexibility is crucial when a biologic portfolio spans several indications and dosing regimens.
Background on Schott Pharma shares
SyriQ BioPure is part of Schott Pharma’s portfolio of containment solutions for injectable drugs, a segment that investors follow closely when they assess growth in biologics and prefillable syringe systems.
What clinicians notice at the bedside
When a nurse picks up a syriQ BioPure syringe on the ward, the main difference is subtle but real: the plunger force is steady, without the sudden stick-slip that can jolt a sensitive subcutaneous injection. That makes injections more predictable for both staff and patients.
The clear, scratch-resistant glass barrel keeps the solution easy to inspect against the light before injection, letting clinicians spot any visible particles or discoloration quickly. In practice, that means fewer last-minute substitutions and smoother therapy routines for complex biologic regimens.
How Schott Pharma positions the product
Chief Executive Officer Andreas Reindl has highlighted prefillable syringes like syriQ BioPure as a strategic pillar in Schott Pharma’s growth story, because biologic drugs continue to gain share within global injectable therapies. The company focuses on containment that supports high-value, high-sensitivity formulations.
Product managers working on the syriQ BioPure line coordinate closely with biopharma clients to fine-tune parameters such as break-loose and glide force, flange design and stopper compatibility. Their goal is to deliver a containment system that integrates into the drug maker’s device ecosystem rather than standing alone.
Where syriQ BioPure fits in the market
SyriQ BioPure competes with other high-end prefillable syringe systems targeted at biologics, including offerings from rival packaging specialists in Europe and Asia. For pharma companies, the choice often hinges on particle performance, extractables profile and compatibility with existing auto-injector platforms.
As more treatments shift from hospital-based intravenous infusions to self-administered subcutaneous injections at home, prefillable syringes become a vital interface between complex formulations and everyday patients. Syringe systems like syriQ BioPure aim to bridge that shift without compromising drug stability.
Context and Schott Pharma shares
Schott Pharma, headquartered in Germany, derives a significant part of its sales from glass and polymer containment solutions for injectable medicines, including prefillable syringes, cartridges and vials. SyriQ BioPure sits in the higher-value segment that caters to biologic and specialty drugs.
Schott Pharma shares (ISIN DE000A3ENQ51) are listed in Frankfurt, and investors watch demand for products like syriQ BioPure as one indicator for the company’s long-term growth in biopharmaceutical packaging.
Key facts on syriQ BioPure
- Product: syriQ BioPure prefillable glass syringe
- Manufacturer: Schott Pharma AG & Co. KGaA
- Category: Flagship/Bestseller prefillable syringe system for biologics
- Launch: Introduced as part of Schott Pharma’s biologics-focused portfolio in recent years
- RRP / Price: Sold B2B, priced per component and contract, not at consumer level
- Availability: Supplied globally to biopharmaceutical manufacturers, with a focus on Europe, North America and Asia
- Target group: Biopharma companies filling sensitive biologic and protein-based injectable drugs
- Highlight / USP: Prefillable glass syringe system optimized to reduce particle formation and interaction for biologic formulations
This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.
